Tretinoin and Progesterone HRT Interaction: What Patients and Prescribers Need to Know
At a glance
- The pair / topical tretinoin plus progesterone hormone therapy
- Interaction study / we found no published study of the two together
- Renova label interactions / irritating topical products, and drugs known to be photosensitizers [2]
- Progesterone label interactions / one in-vitro ketoconazole finding, clinical relevance unknown [1]
- Progesterone boxed warning / none in the current 02/2026 label revision [1]
- Main labeled effects / skin irritation and photosensitivity from tretinoin; drowsiness and dizziness from oral progesterone [2][3]
Is there a known interaction between topical tretinoin and progesterone?
Neither the Renova label nor the Prometrium label describes an interaction between the two drugs, and we found no published study that tested them together [1][2]. The pair is not listed and has not been studied, so the combination has no label statement and no trial behind it either way.
What the tretinoin labels actually warn about
The Renova (tretinoin cream 0.02%) label has a Drug Interactions section, and it is about skin, not about hormones. It says concomitant topical medications, medicated or abrasive soaps, shampoos, cleansers, cosmetics with a strong drying effect, products with high concentrations of alcohol, astringents, spices or lime, permanent wave solutions, electrolysis, hair depilatories or waxes, and other products that may irritate the skin should be used with caution because they may increase irritation [2].
The same label says Renova should not be administered to a patient taking drugs known to be photosensitizers, naming thiazides, tetracyclines, fluoroquinolones, phenothiazines and sulfonamides as examples, because of possible augmented phototoxicity [2]. Progesterone is not among the drugs named in the Renova label [2].
Photosensitivity is the warning that matters most day to day. The 2025 Retin-A Micro label states that tretinoin can cause photosensitivity and advises minimizing UV exposure, not using it until sunburn has healed, and using sunscreen of SPF 15 or higher plus protective clothing every day, even on days that are not sunny. The older Retin-A cream and gel label similarly says sunlight and sunlamp exposure should be minimized and that patients with sunburn should not use the product until fully recovered. HealthRX.com offers tretinoin by prescription.
What the Prometrium label says about interactions
Prometrium is oral micronized progesterone. Its labeled uses are prevention of endometrial hyperplasia in postmenopausal women with a uterus who are taking conjugated estrogens tablets, and secondary amenorrhea [3]. The label has no separate drug-interaction section. Its one interaction statement sits in the Clinical Pharmacology section: progesterone metabolism by human liver microsomes was inhibited by ketoconazole, and the data suggest that ketoconazole or other known inhibitors of this enzyme may increase progesterone bioavailability, but the clinical relevance of the in vitro findings is unknown [1].
The label says progesterone is metabolized primarily in the liver, largely to pregnanediols and pregnanolones, without naming the enzyme responsible [1]. It also does not describe use with estradiol; the label's dosing and studies use conjugated estrogens [3].
Does progesterone change how tretinoin behaves on the skin?
We found no study that measured tretinoin irritation, tolerability or effect in women using progesterone.
What the tretinoin label reports on its own covers most skin complaints. In vehicle-controlled studies of Renova involving 339 patients, almost all reported one or more local reactions such as peeling, dry skin, burning, stinging, erythema and pruritus; 32% had irritation that was severe, led to temporary discontinuation, or led to use of a mild topical corticosteroid, and about 4% discontinued because of adverse reactions [2]. The Retin-A cream and gel label notes that the skin of sensitive people may become excessively red, swollen, blistered or crusted.
For its part, the Prometrium label lists alopecia, pruritus and urticaria among postmarketing reports, which are voluntary reports from a population of uncertain size [3]. Neither label describes an additive skin effect when the two are used together [2][3].
The pregnancy question, where the labels differ
Pregnancy is still possible during perimenopause, even when periods are irregular [4], so the pregnancy wording on both products is worth reading closely.
Tretinoin's wording depends on the product. The Retin-A cream and gel label (2024) says oral tretinoin is teratogenic in animals, that topical animal results are equivocal, that 30 human cases of temporally associated malformations were reported over two decades of Retin-A use without a causal association established, and that there are no adequate and well-controlled studies in pregnant women. The 2025 Retin-A Micro label says decades of published prospective and retrospective studies have not established a drug-associated risk of major birth defects, miscarriage or adverse outcomes, while noting their methodologic limitations. The Renova label says not to use it if the patient is pregnant, attempting to become pregnant, or at high risk of pregnancy [2].
None of the tretinoin labels reviewed calls the drug contraindicated in pregnancy, and the Renova label's contraindication is limited to hypersensitivity to its components [2]. Some generic tretinoin labels print Pregnancy Category C.
The Prometrium label says the capsules should not be used during pregnancy, while also still carrying a Pregnancy Category B paragraph [1].
Timing and the evening dose
The Prometrium label directs a single daily dose at bedtime and says the drug may cause transient dizziness and drowsiness, with caution when driving a motor vehicle or operating machinery [3][1]. During initial therapy, a few women have had extreme dizziness or drowsiness, blurred vision, slurred speech, difficulty walking, loss of consciousness, vertigo, confusion or feeling drunk [1].
Tretinoin is also an evening product: Retin-A cream and gel are applied once daily before retiring, and Renova once a day in the evening [2]. The two schedules fall in the same part of the day. The Prometrium label describes the drowsiness as an effect of Prometrium itself; it does not link it to any retinoid [3].
What to watch for
Neither the Renova nor the Prometrium label describes a dose adjustment when these two products are used together [2][3]. The cautions that apply are product-specific: tretinoin's local irritation and photosensitivity [2], and progesterone's bedtime dosing because of drowsiness and dizziness [3].
Prometrium's contraindications are also worth knowing: peanut allergy (the capsules contain peanut oil), undiagnosed abnormal genital bleeding, known or suspected breast cancer or a history of it, active or past deep vein thrombosis or pulmonary embolism, active or past arterial thromboembolic disease, and known liver disease [3].
Frequently asked questions
Is there an interaction between topical tretinoin and progesterone HRT?
Does progesterone make tretinoin cause more peeling or redness?
Is tretinoin Pregnancy Category X?
Does the progesterone label warn about CYP3A4 inhibitors?
Why is progesterone taken at bedtime?
References
- U.S. Food and Drug Administration. U.S. Food and Drug Administration
- U.S. National Library of Medicine, DailyMed. Renova tretinoin cream 0.02% (Bausch) prescribing information. Renova tretinoin cream 0.02% (Bausch) label
- U.S. National Library of Medicine, DailyMed. Prometrium progesterone capsules prescribing information. Prometrium progesterone capsules label
- Menopause basics | Office on Women's Health. Menopause basics | Office on Women's Health
- Schüssler P, Kluge M, Yassouridis A, Dresler M, Held K, Zihl J, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2008;33(8):1124-31. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women
- Bulletti C, de Ziegler D, Flamigni C, Giacomucci E, Polli V, Bolelli G, et al. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum Reprod. 1997;12(5):1073-9. Targeted drug delivery in gynaecology: the first uterine pass effect
- Compounding and the FDA: Questions and Answers | FDA. Compounding and the FDA: Questions and Answers | FDA
- American College of Obstetricians and Gynecologists' Committee on Clinical Consensus-Gynecology. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142(5):1266-1273. Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6